1. Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, et al. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. Am J Gastroenterol. 2018;113(2):254-64.

  2. Murillo Perez F, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, et al. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. Hepatology. 2017.

  3. Trivedi PJ, Lammers WJ, van Buuren HR, Pares A, Floreani A, Janssen HL, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. 2016;65(2):321-9.

  4. Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, et al. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology. 2015;149(7):1804-12 e4.

  5. Lammers WJ, Kowdley KV, van Buuren HR. Predicting outcome in primary biliary cirrhosis. Annals of hepatology. 2014;13(4):316-26.

  6. Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;147(6):1338-49 e5; quiz e15.

  7. van Buuren HR, Lammers WJ, Harms MH, Hansen BE. Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis. Dig Dis. 2015;33 Suppl 2:118-24.

 

Oral presentations

  • Harms MH et al. Time trends of Major Hepatic Complications in Primary Biliary Cholangitis: incidence and prognosis. AASLD Liver Meeting 2017, Washington, USA.
  • Goet JC et al. The GLOBE score identifies PBC patients at increased risk of liver transplantation or death over time Digestive Disease Days Nederlandse Vereniging voor Gastroenterologie 2017, Veldhoven, The Netherlands.
  • Harms MH et al. Time trends of Major Hepatic Complications in Primary Biliary Cholangitis: incidence and prognosis. Digestive Disease Days Nederlandse Vereniging voor Gastroenterologie 2017, Veldhoven, The Netherlands.
  • Goet JC et al. The Globe score identifies PBC patients at increased risk of liver transplantation in different age-categories over time. Oral e-poster presentation at EASL The International Liver Congress 2017, Amsterdam, The Netherlands.
  • Harms MH et al. Time trends of Major Hepatic Complications in Primary Biliary Cholangitis: incidence and prognosis. Digestive Disease Days Nederlandse Vereniging voor Gastroenterologie 2017, Veldhoven, The Netherlands.
  • Goet JC et al. The Globe score identifies PBC patients at increased risk of liver transplantation in different age-categories over time. Early Morning Workshop presentation “New therapeutic approaches in PBC” at EASL The International Liver Congress 2017, Amsterdam, The Netherlands.
  • Harms MH et al. Comparable Beneficial Effects of Bezafibrate and Fenofibrate in Primary Biliary Cholangitis. AASLD Liver Meeting 2016, Boston, USA.
  • Harms MH et al. Fibrates in PBC. Early Morning Workshop presentation at AASLD Liver Meeting 2016, Boston, USA.
  • Harms MH et al. Primary biliary Cholangitis at a Young Age – Clinical Characteristics and Prognosis. Digestive Disease Days Nederlandse Vereniging voor Gastroenterologie 2016, Veldhoven, The Netherlands.
  • Harms MH et al. Behavioral Patterns of Total Serum Bilirubin Prior to Major Clinical Endpoints in Primary Biliary Cholangitis. Oral e-poster presentation at EASL International Liver Conference 2016, Barcelona, Spain.
  • Harms MH et al. Improvement in Estimated Survival after 1 Year of Obeticholic Acid Treatment. Oral e-poster presentation at EASL International Liver Conference 2016, Barcelona, Spain.
  • Harms MH et al. Incidence and impact of decompensating events in primary biliary cirrhosis – results of an international follow up study of 3030 patients. AASLD Liver Meeting 2015, San Francisco, USA.
  • van Buuren HR. Surrogate markers for optimal therapeutic response to UDCA  Falk symposium 197 ''Autoimmune diseases of the Liver'' 2015, Lisbon, Portugal.
  • Lammers WJ et al. New model to identify UDCA-treated primary biliary cirrhosis patients in need of additional therapy. Results of an international follow-up study of 4119 patients. AASLD Liver Meeting 2014, Boston, USA.
  • Lammers WJ et al. Validation of alkaline phosphatase and bilirubin values as a surrogate endpoint in primary biliary cirrhosis – international, collaborative study. AASLD 2013, Washinton, USA.


Poster presentations

  • Goet JC et al. Moving from early to moderate or advanced biochemical disease stage during follow-up is associated with an increasing risk of clinical events in primary biliary cholangitis patients. AASLD Liver Meeting 2017, Washington.
  • Goet JC et al. The Globe score identifies PBC patients at increased risk of liver transplantation in different age-categories over time. EASL The International Liver Congress 2017, Amsterdam, The Netherlands.
  • Harms MH et al. Effect of Obeticholic Acid Treatment in patients with Primary Biliary Cholangitis on categorical shifts in the GLOBE score. EASL The International Liver Congress 2017, Amsterdam, The Netherlands.
  • Harms MH et al. Risk reduction with Obeticholic Acid in patients not achieving the POISE primary endpoint. EASL The International Liver Congress 2017, Amsterdam, The Netherlands.
  • Goet JC et al. The Globe score identifies PBC patients at increased risk of liver transplantation or death during follow-up. AASLD Liver Meeting 2016, Boston, USA.
  • Harms MH et al. Association between UDCA therapy and Prolonged Transplant-free Survival among patients with Primary Biliary Cholangitis. AASLD Liver Meeting 2016, Boston, USA.
  • Harms MH et al. Primary biliary Cholangitis at a Young Age – Clinical Characteristics and Prognosis. AASLD Liver Meeting 2016, Boston, USA.
  • Lammers WJ et al. Elevation of alkaline phosphatase during follow-up is an early predictor of hyerbilirubinaemia and of clinical endpoints in primary biliary cirrhosis – an international study. AASLD Liver Meeting 2015, San Francisco, USA.
    Hansen et al. Convergence of two predictive models of risk reduction in patients with primary biliary cirrhosis. AASLD Liver Meeting 2015, San Francisco, USA.
  • Lammers WJ et al. Identification of PBC patients in need of additional therapy during the course of UDCA treatment. EASL The International Liver Congress 2015, Vienna, Austria.
  • Cheung AC et al. The impact of age and sex on biochemical response and transplant-free survival in patients with PBC: results from the Global PBC Study Group. EASL The International Liver Congress 2015, Vienna, Austria.
  • Harms MH et al. Risk factors for hepatic decompensation in primary biliary cirrhosis – results of an international follow up study of 2326 patients. EASL The International Liver Congress 2015, Vienna, Austria.
  • Carbone M et al. Validation of an alkaline phosphatase and bilirubin response criteria as biomarker for transplant-free survival in primary biliary cirrhosis in the worlds’ two largest cohorts. EASL The International Liver Congress 2015, Vienna, Austria.
  • Lammers WJ et al. Sub-stratification of hepatocellular carcinoma risk in men with primary biliary cirrhosis: results of an international multicenter study. AASLD Liver Meeting 2014, Boston, USA.
  • van Buuren HR. Surrogate markers. Evaluation of therapeutic efficacy. EASL Monothematic conference Primary Biliary Cirrhosis 2014, Milan, Italy.
  • Lammers WJ et al. Impact in daily practice of the concept of treatment response in primary biliary cirrhosis. A national cohort study. EASL The International Liver Congress 2014, London, UK.
  • Lammers WJ et al. Alkaline phosphatase values are a surrogate marker in prediction of transplant-free survival in patients with primary biliary cirrhosis – an international, collaborative analysis. EASL 2013, Amsterdam, The Netherlands.